Georgia's Online Cancer Information Center

Find A Treatment Site

Emory University Hospital - Atlanta

Emory University Hospital is a 587 bed facility specializing in the care of the acutely ill adult. Staffed exclusively by School of Medicine faculty who are also members of The Emory Clinic, the hospital is renowned as one of the nation's leaders in cardiology and cardiac surgery, oncology, transplantation and the neurosciences. The mission of Emory University Hospital is to provide excellence in patient care, enhanced by education and research. Emory University Hospital has established a solid foundation for outstanding quality health care, leadership and medical integrity and has been included in U. S. News and World Report's "America's Best Hospitals."

Treatment Sites in Georgia

Primary Location

1364 Clifton Road NE
Atlanta, GA 30322
404-712-2000 (p)
www.emoryhealthcare.org

driving directions

Doctors

Nazmi Volkan Adsay MD
Cletus A. Arciero MD
Bruce J. Barron MD
Deborah A. Baumgarten MD, MPH
Daniel J. Brat MD, PhD
Otis W. Brawley MD
Kenneth Cardona MD
Grant W. Carlson MD
Bradley C. Carthon, MD, PhD
Amy Y. Chen MD
Suephy C. Chen MD, MS
Cynthia Cohen MD
Ian R. Crocker MD, FACR
Walter J Curran, Jr. MD, FACR
Keith A. Delman MD, FACS
Roberto R. Diaz MD
Scott H. Edelman MD
John William Eley MD, MPH
Bassel F El-Rayes MD
Natia Esiashvili MD
Christopher R. Flowers MD
Lisa Flowers MD
Sheryl A. Gabram-Mendola MD, MBA, FACS
Anthony Andrew Gal MD
Jacques Galipeau MD
Karen D. Godette MD
Alan N. Gordon MD
Chunhai Hao MD, PhD
Wayne B. Harris MD
Natalyn N. Hawk MD
Leonard T. Heffner Jr., MD
Bruce W. Hershatter MD
Kristin Higgins MD
Charles E. Hill MD
Ira R. Horowitz MD, SM, FACOG, FACS
Stephen B. Hunter MD
Ashesh B. Jani MD
David L. Jaye MD
Cassandra Josephson MD
Jonathan L. Kaufman MD
Christine L. Kempton MD
Mohammad K Khan MD, PhD
Namita Khanna MD
H. Jean Khoury MD, FACP
David A. Kooby MD
Omer Kucuk MD
J. David Lambeth MD, PhD
Jerome C. Landry MD
Amelia A. Langston MD
Stephen K. Lau MD
Mary Jo Lechowicz MD
Melinda Moore Lewis MD
Shiyong Li MD, PhD
James V. Little MD
Sagar Lonial MD
Shishir K. Maithel MD
Karen P. Mann MD, PhD
Viraj Master MD, PhD
Morgan L. McLemore MD
Mario Mosunjac MD
Peter T. Nieh MD
Ajay K. Nooka MD, MPH
Kenneth Ogan MD
Jeffrey J. Olson MD
Thomas A. Olson MD
Gabriela M. Oprea MD
Suchita Pakkala MD
Douglas C. Parker MD
John G. Pattaras MD
Rathi Pillai MD
Suresh S. Ramalingam MD
William Read , MD
Satyanarayan K. Reddy MD
Maria J. Ribeiro MD
Monica Rizzo MD
Seth A Rosen MD
Peter J. Rossi MD
Maria Russell MD
Nabil F. Saba MD, FACP
Judy H. Sequeira MD
Charles W. Sewell MD
Walid L Shaib
Joseph Shelton MD
Dong Moon Shin MD
Momin T. Siddiqui MD, FIAC
Charles A. Staley MD
Liza J. Stapleford MD
Sidney F. Stein MD
Toncred M. Styblo MD
Talaat S. Tadros MD
Mylin A. Torres MD
Vijay Alluri Varma MD
Edmund K. Waller MD, PhD, FACP
Sharon W. Weiss MD
Ifor R. Williams MD, PhD
Joshua Winer MD
Elliott F. Winton MD

Clinical Trials in Georgia

1. Use of Definity® Contrast Agent for Ultrasound of Intraocular Tumors
Cancer Type: Eye Cancer

A Master Protocol for Biomarker-Based Treatment of AML (The Beat AML Trial)
Cancer Type: Myelodysplastic Syndromes (MDS)

A Multi-Cohort Phase 1b Clinical Trial of Rituximab in Combination with Immunotherapy in Untreated and Previously Treated Follicular Lymphoma
Cancer Type: Unspecified

A Phase 1 / 1b, Open-Label, Dose-Escalation and Expansion Study of Entrectinib (RXDX 101) in Children and Adolescents With Recurrent or Refractory Solid Tumors and Primary CNS Tumors, With or Without TRK, ROS1, or ALK Fusions
Cancer Type: Neuroblastoma

A Phase 1 / 2, Multicenter, Dose-Escalation and Expansion Study of Combination Therapy With Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Subjects With Relapsed or Refractory Multiple Myeloma
Cancer Type: Lymphoma, Multiple Myeloma

A Phase 1 / 2, Open-Label Study of ADXS-503 Alone and in Combination With Pembrolizumab in Subjects With Metastatic Squamous or Non-Squamous Non-Small Cell Lung Cancer
Cancer Type: Lung Cancer, Unknown Primary

A Phase 1 Multiple Dose Study to Evaluate the Safety and Tolerability of XmAb®14045 in Patients With CD123-Expressing Hematologic Malignancies
Cancer Type: Leukemia, Lymphoma, Myelodysplastic Syndromes (MDS), Skin Cancer (Non-Melanoma)

A Phase 1 Multiple Dose Study to Evaluate the Safety and Tolerability of XmAb®18087 in Subjects With Advanced Neuroendocrine and Gastrointestinal Stromal Tumors
Cancer Type: Colon/Rectal Cancer

A Phase 1 Multiple Dose Study to Evaluate the Safety and Tolerability of XmAb®20717 in Subjects With Selected Advanced Solid Tumors
Cancer Type: Endometrial Cancer

A Phase 1 Multiple-Dose Study to Evaluate the Safety and Tolerability of XmAb®23104 in Subjects With Selected Advanced Solid Tumors
Cancer Type: Lung Cancer

A Phase 1 Study of ASP1951 in Subjects With Advanced Solid Tumors
Cancer Type: Lung Cancer, Prostate Cancer , Unknown Primary

A PHASE 1 STUDY TO EVALUATE THE EFFECT OF HEPATIC IMPAIRMENT ON THE PHARMACOKINETICS AND SAFETY OF LORLATINIB IN ADVANCED CANCER PATIENTS
Cancer Type: Lymphoma, Unknown Primary

A Phase 1, Dose Escalation and Expansion Study of Engineered Donor Grafts Derived From Mobilized Peripheral Blood (OrcaGraft), With Single Agent Graft Versus-host Disease Prophylaxis, in Recipients Undergoing Myeloablative Allogeneic Hematopoietic Cell Transplantation for Hematologic Malignancies
Cancer Type: Myelodysplastic Syndromes (MDS)

A Phase 1, First in Human, Dose Escalation Study of MGD006, a CD123 x CD3 Dual Affinity Re-Targeting (DART) Bi-Specific Antibody Based Molecule, in Patients With Relapsed or Refractory Acute Myeloid Leukemia
Cancer Type: Leukemia

A Phase 1, First-in-Human, Open-Label, Dose Escalation and Expansion Study of CUE-101 Monotherapy in Patients With HPV+ Recurrent / Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)
Cancer Type: Skin Cancer (Non-Melanoma), Unknown Primary

A Phase 1b / 2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of EQ001 in Subjects With Newly Diagnosed Acute Graft Versus Host Disease
Cancer Type: Bone and Soft Tissue (including Sarcoma)

A Phase 1b / 2, Open-Label, Multicenter Dose-Escalation and Dose-Expansion Study of the Combination of RMC-4630 and Cobimetinib in Adult Participants With Relapsed / Refractory Solid Tumors With Specific Genomic Aberrations
Cancer Type: Unknown Primary

A Phase 2 / 3, Multicenter, randOmized, Double-blind, Placebo-controlled, stUdy to evaLuate the Safety and Efficacy of Alpha-1 AntiTrypsin for the prEvention of Graft Versus-host Disease in Patients Receiving Hematopoietic Cell Transplant (MODULAATE Study)
Cancer Type: Myelodysplastic Syndromes (MDS)

A Phase 2 Study of Erdafitinib in Subjects With Advanced Solid Tumors and FGFR Gene Alterations
Cancer Type: Unspecified

A Phase 2 Study of Neoadjuvant Cabozantinib in Patients with Locally Advanced Non-Metastatic Clear Cell Renal Cell Carcinoma
Cancer Type: Kidney Cancer, Unknown Primary

A Phase 2, Fast Real-time Assessment of Combination Therapies in Immuno-ONcology Study in Participants With Advanced Gastric Cancer (FRACTION-Gastric Cancer)
Cancer Type: Stomach/ Gastric Cancer

A Phase 2, Open-Label, Multi-Center Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
Cancer Type: Lymphoma, Multiple Myeloma

A Phase 2, Randomized, Open-label Study of Nivolumab or Nivolumab / BMS-986205 Alone or Combined With Intravesical BCG in Participants With BCG-Unresponsive, High-Risk, Non-Muscle Invasive Bladder Cancer
Cancer Type: Bladder Cancer

A Phase 2, Single-Arm Study of Denosumab in Multiple Myeloma Patients with Renal Insufficiency
Cancer Type: Lymphoma, Multiple Myeloma

A Phase 3, Multicenter, Randomized, Double-blind, Double-dummy, Active-controlled Study to Assess the Efficacy and Safety of Maribavir Compared to Valganciclovir for the Treatment of Cytomegalovirus (CMV) Infection in Hematopoietic Stem Cell Transplant Recipients
Cancer Type: Unspecified

A Phase 3, Randomized, Comparator-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in Participants With High-risk Non-muscle Invasive Bladder Cancer (HR NMIBC) That is Persistent or Recurrent Following BCG Induction (KEYNOTE-676)
Cancer Type: Unspecified

A Phase I / II Assessment of Combination Immuno-Oncology Drugs Elotuzumab, Anti-LAG-3 (BMS-986016) and Anti-TIGIT (BMS-986207)
Cancer Type: Unspecified

A Phase I / II Study of Human Placental Hematopoietic Stem Cell Derived Natural Killer Cells (CYNK 001) in Multiple Myeloma Patients Following Autologous Stem Cell Transplant in the Front-line Setting.
Cancer Type: Unspecified

A Phase I / II Study of the PD-1 Antibody Nivolumab in Combination with Lenalidomide in Relapsed / Refractory Non-Hodgkin’s Lymphoma (NHL) and Hodgkin’s Disease (HD)
Cancer Type: Unspecified

A Phase I Dose Escalation Study of the Safety, Pharmacokinetics and Pharmacodynamics of MRX-2843 in Adult Subjects With Relapsed / Refractory Advanced and / or Metastatic Solid Tumors
Cancer Type: Unknown Primary

A Phase I Study of Mesenchymal Stromal Cells for the Treatment of Acute and Chronic Graft versus Host Disease
Cancer Type: Bone and Soft Tissue (including Sarcoma)

A Phase I Study of Neihulizumab (AbGn-168H) in Patients With Steroid-refractory Acute Graft-versus-host Disease (Sr-aGvHD)
Cancer Type: Bone and Soft Tissue (including Sarcoma)

A Phase I Study of Obinutuzumab, Venetoclax, and Lenalidomide in Relapsed and Refractory B-Cell Non-Hodgkin Lymphoma
Cancer Type: Lymphoma

A Phase IIA Study of ABC294640 in the Treatment of Patients With Advanced, Unresectable Intra-hepatic, Perihilar and Extra-Hepatic Cholangiocarcinoma
Cancer Type: Unspecified

A Pilot Study of Atezolizumab (MPDL3280A) following Adoptive Cell Transfer in Active Hematologic or Solid Tumor Malignancies
Cancer Type: Unknown Primary

A Pilot Study of Biomarker Evaluation and Safety of Pre-Incisional Ketorolac for Patients Undergoing Surgical Resection for Non-Small Cell Lung Cancer and Renal Cell Carcinoma
Cancer Type: Unspecified

A Pilot Study of Nelfinavir for the Treatment of Kaposi Sarcoma
Cancer Type: Unspecified

A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Apalutamide in Subjects With High-risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy
Cancer Type: Prostate Cancer , Unknown Primary

A Randomized, Multicenter, Phase III Trial of Tacrolimus / Methotrexate Versus Post-Transplant Cyclophosphamide / Tacrolimus / Mycophenolate Mofetil in Non-Myeloablative / Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation (BMT CTN #1703; Progress III); Companion Study: Microbiome and Immune Reconstitution in Cellular Therapies and Hematopoietic Stem Cell Transplantation (BMT CTN #1801; Mi-Immune)
Cancer Type: Leukemia, Myelodysplastic Syndromes (MDS)

A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy After Induction Treatment for Hormone Receptor Positive (HR+) / HER2-Positive Metastatic Breast Cancer
Cancer Type: Breast Cancer

An International, Phase 2, Open-Label, Randomized Study of BGB-3111 Combined With Obinutuzumab Compared With Obinutuzumab Monotherapy in Relapsed / Refractory Follicular Lymphoma
Cancer Type: Lymphoma

An International, Phase 3, Open-Label, Randomized Study of BGB-3111 Compared With Bendamustine Plus Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (CLL / SLL)
Cancer Type: Leukemia, Lymphoma

An Open-label, First-in-human, Dose-escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Maximum Tolerated Dose and / or Recommended Phase II Dose of the ATR Inhibitor BAY1895344 in Patients With Advanced Solid Tumors and Lymphomas
Cancer Type: Endometrial Cancer

An Open-Label, Multi-Center Trial of SNS-301 Added to Pembrolizumab in Patients With ASPH+ Locally Advanced Unresectable or Metastatic / Recurrent Squamous Cell Carcinoma of the Head and Neck
Cancer Type: Skin Cancer (Non-Melanoma), Unknown Primary

An Open-Label, Randomized Phase 3 Trial of Nivolumab, or Nivolumab Plus Ipilimumab, or Nivolumab Plus Platinum Doublet Chemotherapy Versus Platinum Doublet Chemotherapy in Subjects With Chemotherapy-Naïve Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC)
Cancer Type: Lung Cancer

Biomolecular Effects of Topical Curcumin in HSIL Cervical Neoplasia
Cancer Type: Unknown Primary

Comparative Effectiveness of Early Integrated Telehealth versus In-Person Palliative Care for Patients with Advanced Lung Cancer
Cancer Type: Lung Cancer

Evaluation of Human Immune Responses to Influenza Virus Vaccination in Patients with Lymphoma
Cancer Type: Leukemia

Evaluation of the Impact of A Survivorship Care Plan and Embedded Navigation Tool (ASCENT) in Patients with Prostate Cancer Undergoing Curative-Intent Radiotherapy with Concurrent Androgen Deprivation Therapy (ADT)
Cancer Type: Prostate Cancer

Genistein Supplementation to Mitigate Cardiometabolic Dysfunction in Patients Undergoing Androgen Deprivation Therapy for Prostate Cancer
Cancer Type: Prostate Cancer

Improving Health Literacy in African-American Prostate Cancer Patients
Cancer Type: Prostate Cancer

Investigation of Therapy Response with Amino Acid Analogue Transport PET Imaging
Cancer Type: Prostate Cancer

I-SPY 2 Trial (Investigation of Serial Studies to Predict Your Therapeutic Response With Imaging And moLecular Analysis 2)
Cancer Type: Breast Cancer

Itacitinib Monotherapy for Low Risk Graft-vs-Host Disease
Cancer Type: Unspecified

MLN9708 (Ixazomib) and MLN4924 (Pevonedistat) in Relapsed / Refractory Multiple Myeloma Patients: A Phase 1b Trial
Cancer Type: Lymphoma, Multiple Myeloma

Multicenter Interventional Lymphangioleiomyomatosis (LAM) Early Disease Trial
Cancer Type: Unspecified

Myeloma-Developing Regimens Using Genomics (MyDRUG) (Genomics Guided Multi-arm Trial of Targeted Agents Alone or in Combination With a Backbone Regimen)
Cancer Type: Unspecified

Percutaneous Image Guided Cryoablation of the Intercostobrachial Nerve for Management of Post Mastectomy Pain Syndrome
Cancer Type: Unknown Primary

Phase 1 / 2a Clinical Trial of BI-1206, a Monoclonal Antibody to CD32b (FcYRIIB), in Combination With Rituximab in Subjects With Indolent B-Cell Non-Hodgkin Lymphoma That Has Relapsed or is Refractory to Rituximab
Cancer Type: Lymphoma

Phase II Randomized Placebo-Controlled Clinical Trial of Genistein in Reducing the Toxicity and Improving the Efficacy of Intravesical Therapy
Cancer Type: Bladder Cancer

Pragmatic Phase III Randomized Trial of Proton vs. Photon Therapy for Patients with Non-metastatic Breast Cancer Receiving Comprehensive Nodal Radiation: A Radiotherapy Comparative Effectiveness (RadComp) Consortium Trial
Cancer Type: Unspecified

Randomized Phase II Trial of Niraparib with Standard Combination Radiotherapy and Androgen Deprivation Therapy (ADT) in High Risk Prostate Cancer (with Initial Phase I)
Cancer Type: Unspecified

The Theranostic Approach Towards Personalized Medicine Using Low Dose Y90 Microspheres for Radioembolization Therapeutic Planning (A Phase 2 Study)
Cancer Type: Unspecified

Validation of FACBC as an Early Indicator of Sub-clinical Metastatic Disease among High-Risk Prostate Cancer Patients with Presumed Localized Disease
Cancer Type: Prostate Cancer
**GeorgiaCancerInfo is not a medical practice. This is an informational web site provided by Georgia CORE, a nonprofit striving to provide current and comprehensive information on cancer care in Georgia through this website. If you find erroneous or missing information, please contact us.
Georgia CORE

 

Advancing Cancer Care through Partnerships and Innovation

Georgia CORE is a public-private partnership that creates collaboration among the state’s cancer organizations and institutions to connect more Georgians to quality, personalized cancer care. We welcome you to this one-of-a-kind online information center for all things related to cancer and survivorship care in Georgia.